Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 20/20 | 0.83 |
| ▸ | EGFR | P00533 | 3/20 | 0.69 |
| ▸ | NUDT14 | O95848 | 1/20 | 0.67 |
| ▸ | NUDT5 | Q9UKK9 | 1/20 | 0.67 |
| ▸ | LCK | P06239 | 3/20 | 0.67 |
| ▸ | ITK | Q08881 | 2/20 | 0.67 |
| ▸ | LYN | P07948 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19829248 | 1.00 | BTK (0.83) | BTKEGFRNUDT14NUDT5LCK | |
| SCHEMBL30610155 | 1.00 | BTK (0.83) | BTKEGFRNUDT14NUDT5LCK | |
| SCHEMBL19638900 | 1.00 | BTK (0.83) | BTKEGFRNUDT14NUDT5LCK | |
| SCHEMBL19638194 | 0.95 | BTK (0.91) | BTK | |
| SCHEMBL19649181 | 0.95 | BTK (0.91) | BTK | |
| SCHEMBL30615729 | 0.95 | BTK (0.91) | BTK | |
| SCHEMBL19638196 | 0.95 | BTK (0.91) | BTK | |
| SCHEMBL23223129 | 0.91 | BTK (1.00) | BTKEGFRLCKITK | |
| SCHEMBL17951513 | 0.91 | BTK (1.00) | BTKEGFRLCKITK | |
| SCHEMBL19638144 | 0.91 | BTK (1.00) | BTKEGFRLCKITK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250241918-A1 | NOVEL USE OF PYRAZOLOPYRIMIDINE COMPOUND | Hefei Youyuan Pharmaceutical Co., Ltd. (CN) | 2025-07-31 | — | — | US | claimed |
| EP-3248979-A1 | NOVEL INHIBITOR OF FLT3 KINASE AND USE THEREOF | Hefei Institutes of Physical Sicence, Chinese Academy of Sciences (CN) | 2017-11-29 | — | — | EP | claimed |
| US-20250241918-A1 | NOVEL USE OF PYRAZOLOPYRIMIDINE COMPOUND | Hefei Youyuan Pharmaceutical Co., Ltd. (CN) | 2025-07-31 | — | — | US | disclosed |
| EP-4509125-A1 | NOVEL USE OF PYRAZOLOPYRIMIDINE COMPOUND | Hefei Youyuan Pharmaceutical Co., Ltd. (CN) | 2025-02-19 | — | — | EP | disclosed |
| EP-3248979-B1 | NOVEL INHIBITOR OF FLT3 KINASE AND USE THEREOF | HEFEI INST PHYSICAL SCI CAS (CN) | 2021-04-14 | — | — | EP | disclosed |
| US-10266535-B2 | Inhibitor of FLT3 kinase and use thereof | HEFEI INSTITUTES OF PHYSICAL SCIENCE, CHINESE ACADEMY OF SCIENCES (CN) | 2019-04-23 | — | — | US | disclosed |
| US-20180030054-A1 | NOVEL INHIBITOR OF FLT3 KINASE AND USE THEREOF | HEFEI INSTITUTES OF PHYSICAL SCIENCE, CHINESE ACADEMY OF SCIENCES (CN) | 2018-02-01 | — | — | US | disclosed |
| EP-3248979-A1 | NOVEL INHIBITOR OF FLT3 KINASE AND USE THEREOF | Hefei Institutes of Physical Sicence, Chinese Academy of Sciences (CN) | 2017-11-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180030054-A1 | NOVEL INHIBITOR OF FLT3 KINASE AND USE THEREOF | FLT3, FLT1, FGFR1 | BTK 32/4885EGFR 160/4885NUDT14 3482/4885 |
| US-20250241918-A1 | NOVEL USE OF PYRAZOLOPYRIMIDINE COMPOUND | NLRP3, NLRP1, CASP1 | BTK 2347/4885EGFR 4797/4885NUDT14 1653/4885 |
| US-10266535-B2 | Inhibitor of FLT3 kinase and use thereof | FLT3, FLT1, FGFR1 | BTK 35/4885EGFR 221/4885NUDT14 3033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.